Table 3.
Distribution of reported clinical indication of use for aripiprazole and risperidone.
| Reported Clinical Indications* | Aripiprazole N (%) | Risperidone N (%) | p | ||||
|---|---|---|---|---|---|---|---|
| 3–11 y# | 12–17 y# | Tot | 3–11 y# | 12–17 y# | Tot | ||
| Schizophrenia spectrum and other psychotic disorders | 17 (7.0) | 134 (24.3) | 151 (19.0) | 87 (4.8) | 213 (15.5) | 300 (9.4) | <0.05 |
| Bipolar and related disorders | 15 (6.2) | 70 (12.7) | 85 (10.7) | 249 (13.6) | 208 (15.1) | 457 (14.2) | <0.05 |
| Disruptive, impulse-control, conduct disorders | 59 (24.3) | 69 (12.5) | 128 (16.1) | 334 (18.3) | 214 (15.6) | 548 (17.1) | <0.05 |
| Depressive disorders | 20 (8.2) | 62 (11.2) | 82 (10.3) | 70 (3.8) | 96 (7.0) | 166 (5.2) | <0.05 |
| Autism spectrum disorder | 43 (17.7) | 49 (8.9) | 92 (11.6) | 205 (11.2) | 78 (5.7) | 283 (8.8) | <0.05 |
| Motor disorders | 16 (6.6) | 31 (5.6) | 47 (5.9) | 45 (2.5) | 37 (2.7) | 82 (2.6) | <0.05 |
| Anxiety disorders | 7 (2.9) | 24 (4.3) | 31 (3.9) | 76 (4.2) | 63 (4.6) | 139 (4.3) | <0.05 |
| ADHD** | 29 (11.9) | 21 (3.8) | 50 (6.3) | 549 (30.0) | 264 (19.2) | 813 (25.4) | <0.05 |
| Obsessive-compulsive and related disorders | 8 (3.3) | 16 (2.9) | 24 (3.0) | 24 (1.3) | 35 (2.5) | 59 (1.8) | <0.05 |
| Personality disorders | 4 (1.6) | 15 (2.7) | 19 (2.4) | 46 (2.5) | 40 (2.9) | 86 (2.7) | <0.05 |
| Total Indications | 243 | 552 | 795 | 1,828 | 1,375 | 3,203 | |
*
Reported clinical indications grouped according to the DSMV;
#
y, years;
**
ADHD, attention-deficit and hyperactivity disorders.